Search research articles
Contact Us
Filters
Showing results (451-460 of 564) with videos related to
Page
of 57
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 18, 2011
Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes
Chun-Fang Xu, Nan X Bing, Howard A Ball, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 23, 2024
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3
Petros Grivas, Damien Pouessel, Chandler H Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 30, 2021
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
Scott T Tagawa, Arjun V Balar, Daniel P Petrylak, et al.
ESMO Open
|
August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
R de Wit, C Wülfing, D Castellano, et al.
The Lancet. Oncology
|
September 23, 2014
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial
Cora N Sternberg, Daniel Castellano, Gedske Daugaard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
Howard I Scher, Susan Halabi, Ian Tannock, et al.
Journal for Immunotherapy of Cancer
|
April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Elena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
European Urology
|
August 15, 2016
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer
Nicholas J Vogelzang, Karim Fizazi, John M Burke, et al.
Frontiers in Oncology
|
February 6, 2024
Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis
Majd Al Assaad, Nara Shin, Michael Sigouros, et al.
European Urology
|
July 16, 2019
Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect
Filippo Pederzoli, Marco Bandini, Alberto Briganti, et al.
Page
of 57
Search research articles
Search
Showing results (451-460 of 564) with videos related to
Sort By:
Page
of 57
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 18, 2011
Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes
Chun-Fang Xu, Nan X Bing, Howard A Ball, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 23, 2024
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3
Petros Grivas, Damien Pouessel, Chandler H Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 30, 2021
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
Scott T Tagawa, Arjun V Balar, Daniel P Petrylak, et al.
ESMO Open
|
August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
R de Wit, C Wülfing, D Castellano, et al.
The Lancet. Oncology
|
September 23, 2014
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial
Cora N Sternberg, Daniel Castellano, Gedske Daugaard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
Howard I Scher, Susan Halabi, Ian Tannock, et al.
Journal for Immunotherapy of Cancer
|
April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Elena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
European Urology
|
August 15, 2016
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer
Nicholas J Vogelzang, Karim Fizazi, John M Burke, et al.
Frontiers in Oncology
|
February 6, 2024
Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis
Majd Al Assaad, Nara Shin, Michael Sigouros, et al.
European Urology
|
July 16, 2019
Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect
Filippo Pederzoli, Marco Bandini, Alberto Briganti, et al.
Page
of 57